Castle Biosciences, Inc. Earnings Recaps
Q1 2026
May 8, 2026
Castle Biosciences' shares fell 19.9% post-earnings, driven by investor disappointment likely tied to cautious 2026 revenue guidance given strong reported test volume growth, suggesting market skepticism about sustainability or margin pressures.
Key takeaways
- Q1 revenue reached $83.7 million, supported by 36% year-over-year growth in core test report volumes.
- DecisionDx-Melanoma test reports grew 16% year-over-year, with March hitting a record month.
- TissueCypher volumes surged 58% year-over-year, also achieving an all-time monthly high in March.
- The company raised 2026 revenue guidance to $345-$355 million, a modest increase from prior guidance, reflecting cautious outlook despite strong volume gains.
- New clinical data published and presented reinforce product differentiation but have not translated into more aggressive growth assumptions.
Q3 2025
Nov 4, 2025
Castle Biosciences reported a pivotal quarter highlighted by the launch of AdvanceAD-Tx, a first-in-class gene expression test aimed at improving treatment outcomes for patients with moderate to severe atopic dermatitis.
Key takeaways
- Successfully launched AdvanceAD-Tx, targeting a $33 billion market opportunity in the U.S. for moderate to severe atopic dermatitis.
- Clinical validation shows AdvanceAD-Tx can significantly improve treatment response rates for patients on JAK inhibitors versus traditional therapies.
- Approximately 80% of surveyed clinicians indicated intent to use AdvanceAD-Tx, underscoring strong market receptivity.
- The company plans to explore multiple reimbursement pathways to facilitate patient access and drive early adoption of the test.